C ardiometabolic risk factors are the combined vascular and metabolic components of risk that may lead to a cardiovascular event. There are numerous such factors. Underlying the concept of cardiometabolic risk is an association with excess visceral fat, leading to the dysregulation of the adipokines, the signalling proteins derived from adipose tissue. Changes in the levels of the adipokines -tumour necrosis factor-α, cholesteryl ester transfer protein and adiponectin, for example -can lead to alterations in insulin sensitivity and high-density lipoprotein cholesterol metabolism. At present, specific cardiometabolic risk factors are commonly managed on an individual basis. We are now moving from the era of single risk factor intervention, however, to multiple risk factor intervention in people at high cardiovascular risk, with the additional possibility of using new drug classes to target the underlying cardiometabolic problems more effectively.
Introduction
In recent years, the incidence of diabetes has increased dramatically. Currently, more than two million people in the UK are diagnosed with diabetes. 1 This increase in the UK is mirrored globally; 194 million people worldwide are diagnosed with diabetes. 2 The vast majority have type 2 diabetes (85-95% of the total diabetes population in developed countries and greater levels in developing countries), which continues to advance to epidemic proportions. 2 Patients with type 2 diabetes exhibit a number of risk factors for serious co-morbidities. 3, 4 For this reason, it is important to focus on the combined vascular and metabolic components of risk that may lead to a cardiovascular event. Underlying the concept of this cardiovascular and metabolic (cardiometabolic) risk is the presence of excess visceral fat.
Abdominal obesity
Obesity is considered to be a risk factor for numerous cardiovascular and metabolic diseases. It can be measured using a number of methods, most commonly body mass index (BMI). BMI only provides a general idea of adiposity, however, whilst numerous studies have shown that it is the distribution of fat -for example, visceral as opposed to subcutaneous fat -that is more important in terms of disease risk. [5] [6] [7] Abdominal fat can be divided into three different components: visceral, subcutaneous and retroperitoneal. The differences are important, as it is visceral fat (the fat around and inside the abdominal organs, particularly the liver) that is most strongly linked to an increased risk of cardiovascular disease (CVD) and type 2 diabetes. Studies have shown that the most practical way to determine levels of visceral fat is through measurement of waist circumference. 7 Indeed, it has been suggested that waist circumference should be considered to be a vital sign 7 and that it should be measured alongside other variables, such as blood pressure and BMI. A recent retrospective study has shown a positive correlation between measured waist circumference and insulin resistance -one of the key factors underlying the pathogenesis of type 2 diabetes. Using multivariate regression models to assess the predictive power of variables (waist circumference, log plasma triglycerides, systolic blood pressure, high-density lipoprotein cholesterol [HDL-C] and BMI), waist circumference was the strongest regressor of the five significant covariables. 8 This link between insulin resistance and waist circumference can be partially attributed to the action of visceral adipose tissue.
Adipose tissue is the body's chief energy reserve and is composed of adipocytes embedded in a connective tissue matrix. One of the roles of white adipose tissue (WAT; the organ that defines obesity) is to release free fatty acids (FFAs) in response to changing energy requirements. 9 There has been a longstanding lack of interest in the study of WAT; only in recent years has it moved to a more prominent position in obesity research, 10 particularly since it was shown that adipose tissue actively secretes a selection of bioactive signalling proteins. 11 These proteins are called adipokines and include diverse molecules such as adiponectin, transforming growth factor β (TGF-β), tumour necrosis factor α (TNF-α), plasminogen activator inhibitor-1 (PAI-1) and vascular endothelial growth factor (VEGF). 10 Some of these proteins, such as leptin and adiponectin, are synthesised and produced exclusively by the adipocytes, and are considered to be true adipokines. TNF-α is produced mainly by adipose tissue macrophages and the majority of the other proteins are produced by adipocytes in addition to the stromal-vascular cells. The list of proteins secreted by adipose tissue is increasing as new adipokines are identified. 12 Under normal conditions, adipokines are controlled by numerous factors, such as fat mass, diet and gender. 11 In abdominally obese individuals, however, levels of adipokines appear to be dysregulated. This review will focus on abdominal obesity, and especially the role of adipokines on cardiometabolic risk factors, such as insulin resistance and dyslipidaemia, and the management of these factors in abdominally obese individuals (figure 1) .
Abdominal obesity, inflammation and insulin resistance Obesity is accompanied by a state of chronic, low-grade inflammation, characterised by increased production of proinflammatory adipokines such as TNF-α and interleukin-6 (IL-6), which play a role in the development of atherosclerosis and insulin resistance. 13 Adipose tissue macrophages are responsible for almost all adipose tissue TNF-α expression and significant amounts of IL-6 expression. Recent studies have demonstrated that obesity leads to increased numbers of adipose tissue macrophages and a switch to a pro-inflammatory state that may contribute to insulin resistance. 14, 15 Links have been recognised between diabetes and TNF-α for over 10 years, since it was reported that TNF-α in the obese state plays an important role in insulin resistance. 16 It has also been demonstrated that in muscle biopsy of insulinresistant and type 2 diabetic patients, TNF-α is expressed at greater levels compared to insulin-sensitive subjects. 17 TNF-α induces insulin resistance by disrupting glucose uptake and insulin signalling through decreasing expression of the glucose transporter GLUT4, the insulin receptor and insulin receptor substrate-1 (IRS-1). 18 TNF-α also impairs the ability of IRS-1 to bind to the insulin receptor by inducing serine phosphorylation of IRS-1, which prevents initiation of insulin signalling. 11, 19 TNF-α has also been shown to increase the expression of IL-6, another pro-inflammatory adipokine that plays an important role in the development of insulin resistance. Human adipose tissue is one of the main sites of IL-6 secretion, accounting for 15-35% of circulating levels. As with TNF-α, IL-6 decreases the expression of IRS-1 and the glucose transporter GLUT4. 20 However, recent data suggest that IL-6 may have a positive effect on glucose and lipid metabolism via signal transducer and activator of transcription 3 (STAT3)/AMP-activated protein kinase (AMPK) regulation of hepatic and muscle metabolism. 21, 22 This illustrates the complex nature of the effects these molecules can produce; the role of IL-6 in the development of insulin resistance needs to be fully elucidated.
In contrast to TNF-α and IL-6, levels of adiponectin are decreased in models of obesity, 23 and in patients with CVD and diabetes. 24 Adiponectin is secreted exclusively by adipocytes, and adiponectin levels correlate negatively with the amount of visceral fat. 24 Recent studies have added complexity to definition of the role of adiponectin as low, medium and high molecular weight isoforms of adiponectin have been identified. Although the effects of these different isoforms have not been fully investigated, one study suggests that high molecular weight adiponectin may have proinflammatory effects and increase monocyte secretion of IL-6, whereas low molecular weight adiponectin has opposite effects. 25 In addition, levels of low molecular weight adiponectin were reduced in patients with type 2 diabetes or obesity. Another study suggests that these isoforms mediate glucose and FFA uptake and oxidation in a distinct and time-dependent manner. 26 Hypoadiponectinaemia in adolescents has been shown to be associated with obesity, and particularly with abdominal obesity and insulin resistance independent of general adiposity. 27 Adiponectin has insulin-sensitising effects by decreasing plasma FFA levels, and reducing endogenous glucose production by inhibiting the hepatic gluconeogenic enzymes glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK). 28 Abdominal obesity is associated with reduced levels of adiponectin and increased levels of FFAs. Chronically increased plasma FFAs stimulate gluconeogenesis, induce hepatic and muscle insulin resistance, and impair insulin secretion. These FFA-induced disturbances are referred to as lipotoxicity. 29 Increased plasma levels of FFAs have also recently been shown to induce insulin resistance through activation of the c-Jun N-terminal kinase (JNK) and through increased secretion of TNF-α in vitro and decreased expression of adiponectin. 30 Abdominal obesity and dyslipidaemia: role of cholesteryl ester transfer protein In type 2 diabetes there is also a general association with a cluster of plasma lipid abnormalities, which include reductions in HDL-C (as stated above), an alteration in the structure of the low-density lipoprotein cholesterol (LDL-C) towards a predominance of small, dense atherogenic particles, and increased triglycerides. 31 This lipid profile is associated with a particularly high risk of cardiovascular complications. Both high triglyceride and low HDL-C levels are predictive of CVD, and small-dense LDL-C is highly Cardiovascular disease
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Key: LDL-C = low-density lipoprotein cholesterol; BP = blood pressure; T2DM = type 2 diabetes mellitus; IR = insulin resistance; HDL-C = high-density lipoprotein cholesterol; TNF = tumour necrosis factor; IL = interleukin; TG = triglycerides; PAI = plasminogen activator inhibitor; Glu = glucose proatherogenic due to its propensity to form oxidised LDL and penetrate the vascular epithelium. One of the key components affecting HDL-C metabolism is cholesteryl ester transfer protein (CETP) (figure 2). CETP is another adipokine that is released by adipose tissue, although it is principally produced by the liver. 10 Levels of CETP in adipose tissue have been shown to be increased after a high-cholesterol diet in hamsters. 32 CETP transfers cholesteryl esters from HDL to apolipoprotein B-containing particles, such as very low-density lipoprotein (VLDL) and LDL particles, in exchange for triglycerides. 33 This action results in reduced levels of HDL-C, which is one of the major disturbances in lipid metabolism in patients with type 2 diabetes and is considered a key predictor for risk of coronary heart disease. 34 In the presence of hypertriglyceridaemia, the cholesterol content of HDL results from decreases in the cholesteryl content of the lipoprotein core. Variable increases in triglyceride make the particles smaller and denser, which is in part a function of CETP. 35 Inhibition of CETP would be expected to lead to higher HDL cholesterol: as such, CETP inhibition is being investigated as a novel therapeutic target for reducing the risk of coronary heart disease. 36 Management of cardiometabolic risk factorspharmacological targets of therapies Initial approaches in the treatment of cardiometabolic risk factors should be non-pharmacological and include alterations in diet 37 and increased levels of physical activity. 38 These approaches can be initially effective but additional pharmacotherapy is commonly required to reduce cardiometabolic risk long term.
Treatments for hyperglycaemia
Improving glycaemic control can have a significant effect on diabetes-related complications. An epidemiological extrapolation from the UK Prospective Diabetes Study (UKPDS) predicts that for every 1% reduction in glycosylated haemoglobin (HbA 1C ) there would be an associated 21% reduction in risk for any diabetes-related end point, including both microvascular (37% reduced risk of microvascular complications) and macrovascular (14% reduced risk of myocardial infarction [MI]) complications. 39 Current guidelines recommend a target HbA 1C of < 7% to reduce the risk of complications. 40 Even tighter targets are suggested by the International Diabetes Federation (IDF; HbA 1C < 6.5%). 41 Metformin is recommended as the usual first-line therapy for patients with diabetes as it ameliorates hyperglycaemia without stimulating insulin secretion, promoting weight gain or causing hypoglycaemia. Metformin also reduces risk factors for heart disease such as cholesterol levels, excess body weight and hypertension. 40 , 42 The mechanism of action of metformin is linked to a reduction of hepatic gluconeogenesis, decreased absorption of glucose from the gastrointestinal tract and increased sensitivity to insulin. 43 The most common adverse effects caused by metformin, occurring in 5-20% of patients, include gastrointestinal bloating and discomfort, anorexia, nausea, metallic taste and diarrhoea. 44 As diabetes progresses, additional agents are usually required to achieve glycaemic control. In the UKPDS, approximately 53% of patients required insulin therapy to maintain glycaemic control over a six-year period. 45 The glitazones (pioglitazone and rosiglitazone) are also recommended as possible second-or third-line oral agents for patients with type 2 diabetes, particularly in combination with metformin for obese patients. 40, 46, 47 Glitazones activate peroxisome proliferator-activated receptors (PPARs), specifically PPARγ, a ligand-activated nuclear transcription factor that modulates the expression of the gene-regulated proteins that control glucose and lipid metabolism. Glitazones also reduce circulating concentrations of pro-inflammatory cytokines such as TNF-α and IL-6, which promote insulin resistance. At the same time glitazones increase concentrations of adiponectin, which has insulin-sensitising and antiinflammatory properties. 48 Unlike metformin, glitazones can be used in patients with reduced renal function, and they are better tolerated, without significant gastrointestinal side effects. However, glitazones are not a good option for obese patients as their clinical use is associated with weight gain. Concern regarding the use of glitazones has been raised recently due to a review of clinical trial data showing an increased risk of MI associated with rosiglitazone, 49 although the statistical methods used in this study have been criticised. Subsequent studies have also provided conflicting results around whether this is a class effect. A meta-analysis of rosiglitazone trials lasting for at least 12 months found a 42% increase in risk of MI and a doubling of the risk of heart failure, although no increase in cardiovascular death was observed. 50 In contrast, a meta-analysis of 19 pioglitazone trials showed that the rate of death, MI or stroke was reduced by 18% in patients who received pioglitazone compared with controls. 51 However, similar to the rosiglitazone metaanalysis, treatment with pioglitazone was associated with a significant increase in the risk of heart failure.
Treatments for dyslipidaemia
Dyslipidaemia is an important risk factor for CVD in patients with diabetes. As such, lipid-lowering therapy may help to reduce cardiovascular risk in these patients. The target for therapy should be to reduce total cholesterol to below 4.0 mmol/L or by 25%, whichever is lower, or to reduce LDL-C to below 2.0 mmol/L or by 30%, whichever is lower. 52 Statins are widely used to reduce LDL-C levels and are associated with a significant reduction in risk of all-cause mortality. 53 However, there remains a residual risk of CVD in statin-treated patients. In the Heart Protection Study, 19.8% of patients receiving statin therapy experienced a major cardiovascular event within five years. 54 Adverse events associated with statins include muscle aches/pain, headache, altered liver function, paraesthesiae and gastrointestinal effects (including abdominal pain, flatulence, diarrhoea, nausea and vomiting). 53 Severe muscle damage (rhabdomyolysis) is a very rare but significant side effect of statin therapy. 53 Statins have only a modest effect on HDL-C levels (elevating them by 4-10%); 55 however, patients with type 2 diabetes typically present with a lipid profile characterised by low HDL-C levels and raised triglyceride levels. Fibrates more closely target the dyslipidaemia seen in patients with type 2 diabetes by significantly increasing HDL-C levels and decreasing triglyceride levels. In the Bezafibrate Infarction Prevention (BIP) study, bezafibrate increased HDL-C by 18% and reduced triglycerides by 21% in patients with coronary artery disease. 56 However, results from outcome trials such as the Fenofibrate Intervention for Event Lowering in Diabetes (FIELD) study have been disappointing. Fenofibrate failed to reduce coronary events (the primary end point) significantly in 9,795 patients with type 2 diabetes, although there was a significant 24% reduction in non-fatal MI (p=0.01) and a 21% reduction in coronary revascularisations (p=0.003). 57 Nicotinic acid increases HDL-C by approximately 20% and has been shown to slow the progression of atherosclerosis in patients with known coronary heart disease. 58 Skin flushing is a very common side effect and can be a cause of non-compliance.
Therapies for weight loss
While improving diet and increasing exercise should be the first-line management strategy for overweight or obese patients, many find adhering to lifestyle modification extremely difficult. Patients who do not achieve their target weight by lifestyle measures alone may benefit from agents that promote weight loss, such as orlistat and sibutramine. Orlistat is a lipase inhibitor that reduces absorption of lipids across the gastrointestinal tract. In a meta-analysis of clinical trials, patients receiving orlistat experienced a 2.7 kg greater weight loss than patients receiving placebo. 59 Orlistat has modest positive effects on glycaemic control and LDL-C levels and marginally reduces HDL-C and triglyceride levels. A small study has shown that weight loss with orlistat is associated with decreases in leptin and increases in adiponectin. 60 Side effects associated with orlistat are generally gastrointestinal, such as fatty stool, faecal urgency and oily spotting; they occur in 15-30% of subjects in clinical trials. 59 Sibutramine is a monoamine reuptake inhibitor that acts centrally to promote a feeling of satiety. Treatment with sibutramine results in an average weight loss 4.3 kg greater than placebo in clinical trials. 59 While sibutramine has a modest effect on glycaemic control (reducing HbA 1C by an average 0.3%), it has shown little effect on LDL-C concentrations and the data on HDL-C and triglyceride levels are variable. 61 Two small studies have shown conflicting results with regard to the effect of sibutramine on adiponectin levels. In one study, adiponectin levels remained unchanged by treatment with sibutramine even though modest weight loss was achieved; however, another study observed increases in adiponectin levels. 62, 63 Common side effects include an increase in blood pressure and pulse rate, 59 therefore it should be used with care in patients with high blood pressure.
A current area of interest from the point of view of improving cardiometabolic risk factors and weight management is the recently characterised endocannabinoid system (ECS). The ECS is an endogenous and physiological system with a key role in energy homeostasis. 64 Overactivation of this system is found in association with obesity, leading to promotion of appetite and a range of metabolic abnormalities already described as being associated with increased cardiometabolic risk. Therefore, blockade of the endocannabinoid receptor-1 offers a therapeutic target. At present, the only available endocannabinoid receptor-1 blocker is rimonabant. In clinical trials, rimonabant significantly reduced weight by 3.9 to 5.4 kg more than placebo, [65] [66] [67] [68] with REVIEW a beneficial effect on the proatherogenic lipid profile through significantly lowering plasma triglyceride and increasing HDL-C levels and LDL-C particle size. Approximately half of the effect of rimonabant on HDL-C and triglycerides was reported to be independent of weight loss, which may be explained by direct effects of rimonabant on adipocytes, including impact on the expression of adiponectin. 65 Rimonabant has been associated with a significant increase in adiponectin levels (p=0.001) and reduction in leptin levels after one year of treatment. 67, 68 Levels of the pro-inflammatory cytokine C-reactive protein were also significantly reduced compared with the placebo group (27% vs. 11%, p<0.01).
The efficacy of rimonabant has been studied in 1,047 overweight or obese patients with type 2 diabetes inadequately controlled with metformin or sulphonylureas. 68 In addition to significant placebo-subtracted weight reduction of 3.9 kg, rimonabant improved glycaemic control, with a mean HbA 1C reduction of 0.7% from a baseline of 7.5%. Rimonabant therefore offers the added benefit of not just reducing body weight, but also improving HbA 1C by clinically significant amounts together with improving the lipid profile of patients with type 2 diabetes. Rimonabant is a suitable treatment option in overweight or obese patients with type 2 diabetes to complement diet, metformin and sulphonylureas as well as statins and other therapies to reduce cardiometabolic risk further.
Adipocyte fatty acid binding protein
Adipocyte fatty acid binding protein aP2 (FABP4) has recently been identified as a potential therapeutic target for the prevention and treatment of type 2 diabetes and atherosclerosis. aP2, which is expressed in adipocytes and macrophages, integrates inflammatory and metabolic responses and is implicated in the development of insulin resistance, obesity, lipid transport disorders and atherosclerosis. 69, 70 An initial study using animal models and cell lines has demonstrated the possibility of specifically targeting this molecule.
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Conclusion
The importance of increased visceral fat as an independent cardiometabolic risk factor is now being appreciated. The mechanistic link between visceral fat, insulin resistance and alteration in lipid metabolism is becoming better understood, with an apparently important role for adipokines in this process. We are also moving from the era of single risk factor intervention to multiple risk factor intervention in people at high cardiovascular risk, with the emerging possibility of using new drug classes to target the underlying cardiometabolic problems more effectively, perhaps at an earlier stage in the disease process. This should always form part of a holistic approach to management, which should include attention to diet and exercise.
